Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24919837,half-time,"Oral absorption was relatively slow, with a half-time of 1.14 h and a lag-time of 0.87 h; time to peak concentration was 5-6 h.",Population pharmacokinetic and pharmacodynamic analysis of bosutinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24919837/),h,1.14,1855,DB06616,Bosutinib
,24919837,lag-time,"Oral absorption was relatively slow, with a half-time of 1.14 h and a lag-time of 0.87 h; time to peak concentration was 5-6 h.",Population pharmacokinetic and pharmacodynamic analysis of bosutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24919837/),h,0.87,1856,DB06616,Bosutinib
,24919837,time to peak concentration,"Oral absorption was relatively slow, with a half-time of 1.14 h and a lag-time of 0.87 h; time to peak concentration was 5-6 h.",Population pharmacokinetic and pharmacodynamic analysis of bosutinib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24919837/),h,5-6,1857,DB06616,Bosutinib
,24919837,Apparent clearance,Apparent clearance was 120 L/h.,Population pharmacokinetic and pharmacodynamic analysis of bosutinib. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24919837/),[l] / [h],120,1858,DB06616,Bosutinib
,24919837,alpha,"The apparent volume of the peripheral compartment was large with a slow turnover; alpha and beta half-lives were 19 h and 290 days, respectively.",Population pharmacokinetic and pharmacodynamic analysis of bosutinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24919837/),h,19,1859,DB06616,Bosutinib
,24919837,beta half-lives,"The apparent volume of the peripheral compartment was large with a slow turnover; alpha and beta half-lives were 19 h and 290 days, respectively.",Population pharmacokinetic and pharmacodynamic analysis of bosutinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24919837/),d,290,1860,DB06616,Bosutinib
,25803093,peak plasma concentration (C(max),"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[ng] / [ml],112,17469,DB06616,Bosutinib
,25803093,peak plasma concentration (C(max),"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[ng] / [ml],16.0,17470,DB06616,Bosutinib
,25803093,total area under the concentration-time curve (AUC,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],2740,17471,DB06616,Bosutinib
,25803093,total area under the concentration-time curve (AUC,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],207,17472,DB06616,Bosutinib
,25803093,AUC to the last measurable concentration at time T,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],2440,17473,DB06616,Bosutinib
,25803093,AUC to the last measurable concentration at time T,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],158,17474,DB06616,Bosutinib
,25803093,volume of distribution,"Oral clearance increased approximately 13-fold; the volume of distribution increased from 9560 to 72,900 L.","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),l,9560,17475,DB06616,Bosutinib
,25803093,volume of distribution,"Oral clearance increased approximately 13-fold; the volume of distribution increased from 9560 to 72,900 L.","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),l,"72,900",17476,DB06616,Bosutinib
,31518862,flow rate,Acetonitrile and 0.1% formic acid in water were employed as the mobile phase in a mode of gradient elution with the 0.40 mL/min flow rate.,Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518862/),[ml] / [min],0.40,30760,DB06616,Bosutinib
,31518862,m/,"Multiple reaction monitoring (MRM) was used to monitor the precursor-to-product ion transitions of m/z 405.4 → 84.1 for eliglustat and m/z 530.2 → 141.2 for bosutinib (IS), respectively.",Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518862/),,405.4,30761,DB06616,Bosutinib
,25540064,PFS,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,21,36679,DB06616,Bosutinib
,25540064,OS rates,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,43,36680,DB06616,Bosutinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,63.6,44834,DB06616,Bosutinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,38.2,44835,DB06616,Bosutinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,60.9,44836,DB06616,Bosutinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,52.6,44837,DB06616,Bosutinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,86.7,44838,DB06616,Bosutinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,76.7,44839,DB06616,Bosutinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,81.5,44840,DB06616,Bosutinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,76.3,44841,DB06616,Bosutinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],17.2,50813,DB06616,Bosutinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],33.1,50814,DB06616,Bosutinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],27.7,50815,DB06616,Bosutinib
,31499430,flow rate,"The purpose of chromatographic separation of talazoparib and the internal standard (bosutinib) was achieved on an Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column with a flow rate of 0.40 mL/min, using a gradient elution with acetonitrile and 0.1% formic acid in water as the mobile phase.",UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31499430/),[ml] / [min],0.40,57779,DB06616,Bosutinib
,31499430,m/,"The detection was performed on a XEVO TQ-S triple quadrupole tandem mass spectrometer coupled with electrospray ionization interface under positive-ion multiple reaction monitoring (MRM) mode with the precursor-to-product ion transitions of m/z 381.3 → 285.2 for talazoparib and m/z 530.2 → 141.2 for bosutinib (IS), respectively.",UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31499430/),,530.2,57780,DB06616,Bosutinib
,31499430,m/,"The detection was performed on a XEVO TQ-S triple quadrupole tandem mass spectrometer coupled with electrospray ionization interface under positive-ion multiple reaction monitoring (MRM) mode with the precursor-to-product ion transitions of m/z 381.3 → 285.2 for talazoparib and m/z 530.2 → 141.2 for bosutinib (IS), respectively.",UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31499430/),,141.2,57781,DB06616,Bosutinib
,23053269,Time to C(max),"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,4,93531,DB06616,Bosutinib
,23053269,Time to C(max),"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,2.5,93532,DB06616,Bosutinib
,23053269,Time to C(max),"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,2.0,93533,DB06616,Bosutinib
,23053269,Time to C(max),"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,1.5,93534,DB06616,Bosutinib
,23053269,elimination half-life,"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,55,93535,DB06616,Bosutinib
,23053269,elimination half-life,"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,86,93536,DB06616,Bosutinib
,23053269,elimination half-life,"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,113,93537,DB06616,Bosutinib
,23053269,elimination half-life,"Time to C(max) decreased from 4 h in healthy subjects to 2.5, 2.0, and 1.5 h in Child-Pugh A, B, and C patients, respectively; the elimination half-life increased from 55 h in healthy subjects to 86, 113, and 111 h in Child-Pugh A, B, and C patients.",Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053269/),h,111,93538,DB06616,Bosutinib
,33613287,flow rate,"An Acquity UPLC BEH reverse-phase C18 column (2.1 mm × 50 mm, 1.7 μm) was used for chromatographic separation of fedratinib and bosutinib (as internal standard (IS) in our study) under a linear gradient elution of the mobile phase, which was composed of solution A (acetonitrile) and solution B (water with 0.1% formic acid), along with 0.40 ml/min flow rate.",In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33613287/),[ml] / [min],0.40,109972,DB06616,Bosutinib
,30919310,plasma:brain ratio,"Our results indicate that the effective dose of Nilotinib has the lowest plasma:brain ratio (1%) followed by Bosutinib and Radotinib (5%), Bafetinib (12%) and LCB-03-0110 (12%).",Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919310/),%,1,115901,DB06616,Bosutinib
,30919310,plasma:brain ratio,"Our results indicate that the effective dose of Nilotinib has the lowest plasma:brain ratio (1%) followed by Bosutinib and Radotinib (5%), Bafetinib (12%) and LCB-03-0110 (12%).",Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919310/),%,5,115902,DB06616,Bosutinib
,30919310,plasma:brain ratio,"Our results indicate that the effective dose of Nilotinib has the lowest plasma:brain ratio (1%) followed by Bosutinib and Radotinib (5%), Bafetinib (12%) and LCB-03-0110 (12%).",Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919310/),%,12,115903,DB06616,Bosutinib
,22884766,C(max),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[ng] / [ml],58.4,130017,DB06616,Bosutinib
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],2980,130018,DB06616,Bosutinib
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],"23,000",130019,DB06616,Bosutinib
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],876,130020,DB06616,Bosutinib
,22884766,AUC(0-24),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],876,130021,DB06616,Bosutinib
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],7080,130022,DB06616,Bosutinib
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],2740,130023,DB06616,Bosutinib
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],"22,200",130024,DB06616,Bosutinib
>,32971496,recovery,"The recovery of each substance was > 81.0%, and no significant matrix effects were observed.","Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32971496/),%,81.0,154095,DB06616,Bosutinib
,23839484,maximum plasma concentration (C(max)),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[ng] / [ml],70.2,157625,DB06616,Bosutinib
,23839484,maximum plasma concentration (C(max)),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[ng] / [ml],42.9,157626,DB06616,Bosutinib
,23839484,total area under the plasma concentration-time curve (AUC),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[h·ng] / [ml],"1,940",157627,DB06616,Bosutinib
,23839484,total area under the plasma concentration-time curve (AUC),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[h·ng] / [ml],"1,470",157628,DB06616,Bosutinib
,23839484,apparent total body clearance,"Mean apparent total body clearance from plasma after oral administration increased from 237 to 330 L/h, and the median time to reach Cmax increased from 5 to 6 h, although this change may be related to decreased bosutinib absorption when combined with lansoprazole.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[l] / [h],237 to 330,157629,DB06616,Bosutinib
,23839484,time to reach Cmax,"Mean apparent total body clearance from plasma after oral administration increased from 237 to 330 L/h, and the median time to reach Cmax increased from 5 to 6 h, although this change may be related to decreased bosutinib absorption when combined with lansoprazole.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),h,5,157630,DB06616,Bosutinib
,32095071,Multiple,"Multiple reaction monitoring transitions were 393→337 and 393→309 for dovitinib, and 530→141 and 530→113 for bosutinib.","A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095071/),,39,158200,DB06616,Bosutinib
,32095071,Multiple,"Multiple reaction monitoring transitions were 393→337 and 393→309 for dovitinib, and 530→141 and 530→113 for bosutinib.","A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095071/),,393,158201,DB06616,Bosutinib
,32095071,Multiple,"Multiple reaction monitoring transitions were 393→337 and 393→309 for dovitinib, and 530→141 and 530→113 for bosutinib.","A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095071/),,530,158202,DB06616,Bosutinib
,32095071,recovery,"Furthermore, the dilution integrity of the method was demonstrated by good recovery (97-99%) and RSD values (0.5-0.7%).","A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095071/),%,97-99,158203,DB06616,Bosutinib
,32095071,RSD,"Furthermore, the dilution integrity of the method was demonstrated by good recovery (97-99%) and RSD values (0.5-0.7%).","A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095071/),,0.5-0.7,158204,DB06616,Bosutinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],89.2,200125,DB06616,Bosutinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],141.1,200126,DB06616,Bosutinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200127,DB06616,Bosutinib
,33214787,maximum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200128,DB06616,Bosutinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],16.7,200129,DB06616,Bosutinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],141.1,200130,DB06616,Bosutinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200131,DB06616,Bosutinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[h·ng] / [ml],1278.5,200132,DB06616,Bosutinib
,33214787,area under the plasma concentration-time curve,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[h·ng] / [ml],1017.4,200133,DB06616,Bosutinib
,33214787,area under the plasma concentration-time curve,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[h·ng] / [ml],1278.5,200134,DB06616,Bosutinib
,21691746,time to C (max),Absorption was relatively slow; median time to C (max) was 6 h.,"A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21691746/),h,6,202301,DB06616,Bosutinib
,21691746,Apparent volume of distribution (V (z)/F),"Apparent volume of distribution (V (z)/F) was 131-214 L/kg, mean apparent clearance (CL/F) was 2.25-3.81 L/h/kg, and mean terminal elimination half-life (t (1/2)) was 32-39 h.","A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21691746/),[l] / [kg],131-214,202302,DB06616,Bosutinib
,21691746,apparent clearance (CL/F),"Apparent volume of distribution (V (z)/F) was 131-214 L/kg, mean apparent clearance (CL/F) was 2.25-3.81 L/h/kg, and mean terminal elimination half-life (t (1/2)) was 32-39 h.","A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21691746/),[l] / [h·kg],2.25-3.81,202303,DB06616,Bosutinib
,21691746,terminal elimination half-life (t (1/2)),"Apparent volume of distribution (V (z)/F) was 131-214 L/kg, mean apparent clearance (CL/F) was 2.25-3.81 L/h/kg, and mean terminal elimination half-life (t (1/2)) was 32-39 h.","A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21691746/),h,32-39,202304,DB06616,Bosutinib
,27718000,AUCinf,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[h·ng] / [ml],4719,222551,DB06616,Bosutinib
,27718000,AUCinf,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[h·ng] / [ml],2268,222552,DB06616,Bosutinib
,27718000,C max,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[ng] / [ml],146.0,222553,DB06616,Bosutinib
,27718000,C max,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[ng] / [ml],94.94,222554,DB06616,Bosutinib
,27718000,terminal elimination half-life,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,25.99,222555,DB06616,Bosutinib
,27718000,terminal elimination half-life,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,27.79,222556,DB06616,Bosutinib
,27718000,time to C max,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,6.02,222557,DB06616,Bosutinib
,27718000,time to C max,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,4.15,222558,DB06616,Bosutinib
,27718000,apparent oral clearance (CL/F),"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[l] / [h],105.9,222559,DB06616,Bosutinib
,27718000,apparent oral clearance (CL/F),"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[l] / [h],220.4,222560,DB06616,Bosutinib
,26454795,extraction recovery,"The extraction recovery was in the range of 75.6-85.6% for bosutinib and 81.2% for pirfenidone (internal standard, IS).",A simple method for the determination of Bosutinib in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26454795/),%,75.6-85.6,242230,DB06616,Bosutinib
,26454795,extraction recovery,"The extraction recovery was in the range of 75.6-85.6% for bosutinib and 81.2% for pirfenidone (internal standard, IS).",A simple method for the determination of Bosutinib in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26454795/),%,81.2,242231,DB06616,Bosutinib
,29058816,terminal half-life,"Results of plasma pharmacokinetics analyses demonstrated that exposure to intravenous bosutinib was 3-fold higher than for oral bosutinib (16.2 and 5.5 ng·h/mL/mg, respectively), and mean terminal half-life was similar (35.5 and 31.7 hours).","Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29058816/),h,35.5,251714,DB06616,Bosutinib
,29058816,terminal half-life,"Results of plasma pharmacokinetics analyses demonstrated that exposure to intravenous bosutinib was 3-fold higher than for oral bosutinib (16.2 and 5.5 ng·h/mL/mg, respectively), and mean terminal half-life was similar (35.5 and 31.7 hours).","Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29058816/),h,31.7,251715,DB06616,Bosutinib
,29058816,absolute bioavailability,Bosutinib exhibited an absolute bioavailability of 33.85% based on the ratio of AUC0-∞ /D.,"Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29058816/),%,33.85,251716,DB06616,Bosutinib
,29274040,flow rate,"Binary solvent system consisted of 35% solvent A (0.1% formic acid in H2O, pH: 3.2) and 65% solvent B (acetonitrile) used as mobile phase at flow rate of 0.25 mL with a total run time of 5 min.",LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29274040/),ml,0.25,255322,DB06616,Bosutinib
,29274040,total run time,"Binary solvent system consisted of 35% solvent A (0.1% formic acid in H2O, pH: 3.2) and 65% solvent B (acetonitrile) used as mobile phase at flow rate of 0.25 mL with a total run time of 5 min.",LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29274040/),min,5,255323,DB06616,Bosutinib
,29274040,Injection volume,Injection volume was 5 µL.,LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29274040/),μl,5,255324,DB06616,Bosutinib
,29274040,t1/2,In vitro t1/2 was 50.38 min and CLin was 3.11 ± 0.2.,LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29274040/),min,50.38,255325,DB06616,Bosutinib
,29274040,CLin,In vitro t1/2 was 50.38 min and CLin was 3.11 ± 0.2.,LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29274040/),,3.11,255326,DB06616,Bosutinib
,27717999,AUCinf,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[h·ng] / [ml],1182,260008,DB06616,Bosutinib
,27717999,AUCinf,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[h·ng] / [ml],1186,260009,DB06616,Bosutinib
,27717999,C max,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[ng] / [ml],129.8,260010,DB06616,Bosutinib
,27717999,C max,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[ng] / [ml],114.1,260011,DB06616,Bosutinib
,27717999,time to maximum concentration,The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy.,"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),h,2.99,260012,DB06616,Bosutinib
,27717999,time to maximum concentration,The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy.,"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),h,3.99,260013,DB06616,Bosutinib
less,32250458,ki,All three compounds showed a strong reversible inhibition on CYP2C8 enzyme with ki of less than 0.5 μmol L-1 .,"Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),[μM] / [l],0.5,267402,DB06616,Bosutinib
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.0,267403,DB06616,Bosutinib
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.1,267404,DB06616,Bosutinib
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.4,267405,DB06616,Bosutinib
,32250458,AUC ratio,"The PBPK simulation predicted that at recommended dosing regimens of S. sphenanthera, co-administration would result in an increase in bosutinib exposure (AUC ratio 3.0) but not in imatinib exposure.","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,3.0,267406,DB06616,Bosutinib
,15958584,IC(50),SKI-606 inhibited Src autophosphorylation with an IC(50) of approximately 0.25 micromol/L in HT29 cells.,"SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15958584/),[μM] / [l],0.25,268909,DB06616,Bosutinib
,15958584,IC(50)s,"Antiproliferative activity on plastic did not correlate with Src inhibition in either HT29 or Colo205 cells (IC(50)s, 1.5 and 2.5 micromol/L, respectively), although submicromolar concentrations of SKI-606 inhibited HT29 cell colony formation in soft agar.","SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15958584/),[μM] / [l],1.5,268910,DB06616,Bosutinib
,15958584,IC(50)s,"Antiproliferative activity on plastic did not correlate with Src inhibition in either HT29 or Colo205 cells (IC(50)s, 1.5 and 2.5 micromol/L, respectively), although submicromolar concentrations of SKI-606 inhibited HT29 cell colony formation in soft agar.","SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15958584/),[μM] / [l],2.5,268911,DB06616,Bosutinib
,15958584,peak plasma concentrations,"On oral administration to nude mice at the lowest efficacious dose, peak plasma concentrations of approximately 3 micromol/L, an oral bioavailability of 18%, and a t(1/2) of 8.6 hours were observed.","SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15958584/),[μM] / [l],3,268912,DB06616,Bosutinib
,15958584,oral bioavailability,"On oral administration to nude mice at the lowest efficacious dose, peak plasma concentrations of approximately 3 micromol/L, an oral bioavailability of 18%, and a t(1/2) of 8.6 hours were observed.","SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15958584/),%,18,268913,DB06616,Bosutinib
,15958584,t(1/2),"On oral administration to nude mice at the lowest efficacious dose, peak plasma concentrations of approximately 3 micromol/L, an oral bioavailability of 18%, and a t(1/2) of 8.6 hours were observed.","SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15958584/),h,8.6,268914,DB06616,Bosutinib
,21148045,terminal half-life,Ketoconazole coadministration decreased the mean apparent clearance of bosutinib approximately 9-fold and increased the mean (SD) terminal half-life from 46.2 (16.4) hours to 69.0 (29.1) hours.,Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21148045/),h,46.2,272526,DB06616,Bosutinib
,21148045,terminal half-life,Ketoconazole coadministration decreased the mean apparent clearance of bosutinib approximately 9-fold and increased the mean (SD) terminal half-life from 46.2 (16.4) hours to 69.0 (29.1) hours.,Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21148045/),h,69.0,272527,DB06616,Bosutinib
